For individuals with symptomatic disease demanding therapy, ibrutinib is commonly proposed based on four stage III randomized clinical trials evaluating ibrutinib with chlorambucil monotherapy106 and also other usually utilized CIT combos, namely FCR, bendamustine furthermore rituximab and chlorambucil in addition obinutuzumab (ClbO).107–109 Ibru